German pharmaceutical company Bayer reported on Wednesday that the first trials showed that an experimental treatment for Parkinson's disease using stem cells is well tolerated in humans and that the transplanted cells survive in the brains of patients.
Source. Reuters writes about it.
The trial was conducted on 12 volunteers. The first phase lasted more than a year.
The drugmaker noted that the positive results of the first phase using a drug called bemdaneprocel, manufactured by Bayer's subsidiary BlueRock Therapeutics, allowed it to move to the second of three phases of human trials.
Background. Earlier, the US regulator refused to approve the first Alzheimer's drug in almost 20 years. Experts believe that this drug can do more harm than good.